We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Cell Therapeutics issues $15mm in preferred shares
07 May 2009
Executive Summary
Cell Therapeutics (cancer) raised $15mm through the sale to Cranshire Capital of 15k Series 1 preferred shares for $1k each and five-year warrants to purchase 22.5mm common shares at an exercise price of $0.41 apiece. The preferred shares convert to common at $0.30 each, or an aggregate of 50mm common shares. The investor also has a 60-day option to buy an additional $5mm of Series 1 shares (and no additional warrants) under the same terms as the initial purchase. Rodman & Renshaw was the placement agent.
Deal Industry
Biotechnology
Pharmaceuticals
Deal Status
Final
Deal Type
Financing
Other
Private Placement
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?